This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

União Química seeks approval from Brazil’s CADE for acquisition of Bayer’s hormonal therapy drugs

By Maria Júlia Baumert ( October 23, 2024, 18:08 GMT | Insight) -- Pharmaceutical company União Química Farmacêutica Nacional has submitted a full-form notification to the Brazilian competition authority for its proposed acquisition of manufacturing, commercialization, and intellectual property rights for the hormonal therapy drugs Primogyna and Cicloprimogyna from Bayer AG.Pharmaceutical company União Química Farmacêutica Nacional has submitted a full-form notification to the Brazilian competition authority regarding its proposed acquisition of manufacturing, commercialization, and intellectual property rights for the hormonal therapy drugs Primogyna and Cicloprimogyna from Bayer AG. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login